|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
TNF inhibitor
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2008
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Cimzia
|
|
gptkbp:class
|
gptkb:monoclonal_antibody
|
|
gptkbp:clinical_trial
|
gptkb:healthcare_organization
Phase III
autoimmune disorders
chronic inflammatory diseases
dermatological conditions
|
|
gptkbp:contraindication
|
active infections
severe heart failure
history of tuberculosis
|
|
gptkbp:developer
|
UCBS. A.
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:frequency
|
every 2 to 4 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
certolizumab pegol
|
|
gptkbp:indication
|
gptkb:Hidradenitis_suppurativa
gptkb:psoriatic_arthritis
non-infectious uveitis
pediatric Crohn's disease
pediatric ulcerative colitis
|
|
gptkbp:ingredients
|
gptkb:certolizumab
C6420 H9924 N1696 O1984 S44
|
|
gptkbp:invention
|
2025
|
|
gptkbp:is_used_for
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
gptkb:ankylosing_spondylitis
|
|
gptkbp:lifespan
|
14 days
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:rounds
|
renal
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
abdominal pain
diarrhea
rash
increased risk of infections
injection site reactions
upper respiratory infections
|
|
gptkbp:social_structure
|
pegylated
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:bfsParent
|
gptkb:Cimzia
|
|
gptkbp:bfsLayer
|
5
|